Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 17, 2026
HeartFlow (HTFL) Shares Rise +54.4% in 30 Days Following Strong Q2 Results and Guidance Increase

HeartFlow (HTFL) Shares Rise +54.4% in 30 Days Following Strong Q2 Results and Guidance Increase

Key Takeaways

  • HeartFlow shares rose about 54.4% in the 30 days through the August 14, 2026 close, from $27.25 on July 15 to $42.08.
  • The advance was led by second-quarter results: revenue of $64.1 million, up roughly 48% year over year, and an adjusted loss of $0.07 per share that beat consensus expectations for a wider loss.
  • Management raised full-year 2026 revenue guidance to $246 million–$250 million, implying 40%–42% growth, and increased its gross-margin outlook.
  • HTFL climbed 35.7% on August 14 alone, and multiple analysts raised price targets in response.
  • The company is not yet profitable, leaving execution, valuation, and insider-selling trends as key watch items.

HeartFlow (HTFL) Company Overview and Market Position

HeartFlow, Inc. is a commercial-stage medical technology company headquartered in San Francisco, California. It uses artificial intelligence and computational fluid dynamics to convert a single coronary CT angiography (CCTA) scan into a personalized, three-dimensional model of a patient’s coronary arteries. The resulting analysis helps physicians quantify blood flow, identify blockages, and assess plaque burden and composition without invasive testing.

Its platform includes HeartFlow FFRCT Analysis, Plaque Analysis, and RoadMap Analysis, with a fourth product, PCI Planner, expected to launch in 2026. The company says its technology has been studied in more than 100 clinical studies involving over 130,000 patients and published in more than 600 peer-reviewed clinical publications. HeartFlow went public on Nasdaq in August 2025 and is followed by investors as an AI-enabled diagnostics name with a U.S. market opportunity it estimates at about $5 billion for its FFRCT and Plaque products.

HeartFlow (HTFL) Stock Price Performance: Last 30 Days vs. Quarter

Over the 30 days ended August 14, 2026, HTFL advanced about 54.4%, rising from a July 15 close of $27.25 to $42.08. Much of that gain came in a single session: the stock jumped 35.7% on August 14 following second-quarter results, on volume well above its typical daily average.

The broader trailing three-month trend has also been positive but more volatile. From a close of $28.32 on May 15, 2026, to the August 14 close of $42.08, the stock gained about 48.6%. Within that stretch, HTFL rallied into the mid-$30s in late June, pulled back into the low-to-mid $20s by late July, and then rebounded sharply in early-to-mid August. At $42.08, the stock sits near its 52-week high and above its 50-day and 200-day moving averages. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Drove HTFL Stock Price in the Last 30 Days

The dominant catalyst was the company’s second-quarter 2026 report, released after the market closed on August 13. HeartFlow posted revenue of $64.08 million, up 47.7% year over year, and a narrower adjusted net loss of $0.07 per share. Adjusted EBITDA losses narrowed to $6.7 million from $10.1 million a year earlier, and the company reported record gross margin.

Management raised full-year 2026 revenue guidance to a range of $246 million to $250 million, up from $228 million to $232 million previously, implying about 40%–42% revenue growth, and lifted its gross-margin outlook to about 82%. Executives pointed to durable growth in the FFRCT business and accelerating Plaque Analysis adoption. On the other side, the company’s net loss widened to $15.7 million from $9.2 million a year earlier.

The report triggered a wave of analyst target increases. Stifel raised its price target to $45 from $40, JPMorgan moved to $45 from $35, and Wells Fargo lifted its target to $39 from $37, while Piper Sandler reiterated an Overweight rating. Institutional filings also showed increased fund ownership, adding to the supportive backdrop, though insider sales under pre-arranged trading plans remained a counterweight. From what I see, the earnings surprise and guidance lift were the main drivers here.

What Drove HTFL Stock Performance Over the Last Quarter

Over the trailing three months, HTFL’s gains reflect a re-rating of an AI-enabled medtech story that had largely traded sideways to down after its 2025 IPO. The FFRCT franchise provided stable volume growth, while Plaque Analysis emerged as a second growth engine and helped expand account utilization. Management commentary emphasized record gross margin and improving operating leverage, reinforcing the long-term profitability narrative.

The quarter was not a straight line higher. After a strong late-June run into the mid-$30s, shares pulled back through July and traded near the low-to-mid $20s before recovering in August. Hedge-fund data showed rising institutional participation earlier in 2026, and the August earnings beat and guidance raise ultimately validated the constructive view held by most covering analysts. I’m watching this closely as momentum builds.

HTFL Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on whether HeartFlow can sustain FFRCT volume growth, accelerate Plaque Analysis adoption, and deliver the newly raised revenue outlook. The planned 2026 launch of PCI Planner and new clinical studies in asymptomatic patients could expand the addressable market, while updates on gross margin and operating leverage will inform the path toward profitability.

Other watch items include analyst estimate revisions after the guidance increase, macroeconomic sensitivity typical of unprofitable growth companies, competitive developments in AI-enabled cardiac imaging, and ongoing insider-selling patterns disclosed in SEC filings. The company’s next quarterly report will be an important checkpoint for whether current momentum is being converted into sustained execution. One thing that stands out is the potential for further re-rating if execution remains strong.

Using AI Tools for Stock Analysis

In my research process, I occasionally review automated strategies on Tickeron’s Trending AI Robots page. It offers a curated selection of AI-powered trading bots from a platform that provides hundreds of bots trading thousands of tickers. Only top-performing and most relevant strategies appear, and the featured bots vary in approach, timeframe, and performance metrics. The page helps monitor currently favored strategies rather than offering a one-size-fits-all recommendation. Because performance varies, the featured selection can change over time, which is useful for staying informed on evolving approaches.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HTFL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HTFL's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for HTFL moved out of overbought territory on September 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 instances where the indicator moved out of the overbought zone. In 5 of the 5 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In 7 of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 18, 2026. You may want to consider a long position or call options on HTFL as a result. In 23 of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The 10-day moving average for HTFL crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

The 50-day moving average for HTFL moved above the 200-day moving average on August 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +5.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in 70 of 77 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

HTFL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 28 of 41 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.773) is normal, around the industry mean (7.474). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.724). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.134). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. HTFL's P/S Ratio (19.763) is slightly higher than the industry average of (6.065).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.86B. The market cap for tickers in the group ranges from 708 to 42.13B. VEEV holds the highest valuation in this group at 42.13B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 1%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 26%. SDGR experienced the highest price growth at 46%, while CTEV experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -23% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 74
Price Growth Rating: 52
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
HTFL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Details
Industry
N/A
Address
331 East Evelyn Avenue
Phone
+1 650 241-1221
Employees
843
Web
https://www.heartflow.com
Interact to see
Advertisement
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
NEM is trading approximately 9% lower in Thursday premarket, extending Wednesday's 4.56% session loss, as gold prices collapse following the Federal Reserve's hawkish policy hold. Gold spot prices fell 4.21% to $4,616.42 per ounce on March 19, marking the precious metal's sixth straight session of declines — its longest losing streak since late 2024.
Shares of VG are surging approximately +8% in Thursday's premarket session on March 19, 2026, with the stock trading near $16.04, up from the March 18 closing price of $14.85. The primary catalyst is a continuation of bullish momentum driven by a series of analyst price target upgrades, with Scotiabank most recently raising its target from $9 to $11.
LINC shares surged approximately +16% in premarket trading on March 19, 2026, reaching roughly $45.83 from a prior close of $39.51. Primary catalyst: Lincoln Educational Services is hosting its highly anticipated Investor Day today at its brand-new Nashville, TN campus, with presentations beginning at 10:00 am CT (11:00 am ET), live-streamed to investors globally.
PSLV is trading approximately 12% lower in premarket on March 19, 2026, tracking a violent selloff in silver futures. The Federal Reserve's hawkish hold on March 18 — keeping rates at 3.50%–3.75% while signaling fewer cuts ahead — was the primary macro trigger.
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Unusual Machines (UMAC) is trading down approximately -8.60% in premarket on March 20, 2026, extending losses from the prior session. The primary catalyst is a proposed public stock offering announced after the market close on March 19, 2026, raising dilution concerns among investors.
FDX surged approximately 7% in premarket trading on March 20, 2026, moving from the prior session close of $356.11 to around $381. The primary catalyst is a blowout fiscal Q3 2026 earnings report, with adjusted EPS of $5.25 — beating Wall Street's consensus estimate of $4.13 by more than 27%.
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.